Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Dtsch Arztebl Int ; (Forthcoming)2024 11 29.
Artigo em Inglês | MEDLINE | ID: mdl-39297280

RESUMO

BACKGROUND: Dengue fever is a common infectious disease in the tropical and subtropical zones, with more than 100 million symptomatic cases per year. Mosquitoes of the genus Aedes (Aedes aegypti, Aedes albopticus) are vectors of the disease, and their spread has led to rising case numbers around the world. Physicians in Europe, too, are increasingly being confronted by this challenge. METHODS: This review is based on the findings of a selective search in international publication databases, as well as on the WHO guideline of 2009 and the current recommendations of the Robert Koch Institute. RESULTS: Dengue fever takes a mild course in more than 90% of cases. Severe dengue fever, up to and including shock and/or mucosal hemorrhages, is rare and carries a mortality of 1-5%. The disease characteristically takes a triphasic course (febrile phase, critical phase, recovery phase). It is diagnosed by the direct demonstration of the pathogen (e.g., with the reverse transcriptase polymerase chain reaction [RT-PCR] up to day 5 of the illness) or by serology. Patients are classified into one of three risk groups depending on their findings and comorbidities and are then treated either as outpatients or in the hospital. The treatment is symptomatic, as no treatment directed against the cause of the disease is available. The key measures are adequate volume replacement and, in patients with hemorrhage, the transfusion of blood products. Preventive steps include vaccination after a documented initial infection and the meticulous avoidance of mosquito bites. CONCLUSION: Climate change and global mobility have led to a worldwide increase in dengue fever. The disease only rarely takes a severe course. In such cases, rapid symptomatic treatment as needed is the key to the avoidance of severe complications.

2.
IDCases ; 37: e02053, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-39188366

RESUMO

Aerococcus urinae is a gram-positive coccus bacterium with a previously underestimated prevalence due to morphological similarities to other gram-positive cocci. Development of newer diagnostic technologies (such as matrix-assisted laser desorption ionization time-of-flight mass spectrometry MALDI-TOF) led to increased recognition of Aerococcus urinae as causative organism mainly for urinary tract infections. Its antibiotic susceptibility poses some challenges, with resistance to some drugs of choice for urinary tract infection. We report a case of a 69-year-old male with infective endocarditis of the mitral valve, who initially presented with fever and shoulder pain to the emergency department. The patient reported an episode of obstructive renal infection two weeks earlier, which was treated with trimethoprim-sulfamethoxazole. The unusual presentation with shoulder pain and a new heart murmur led to suspicion of endocarditis. Urine and blood cultures were positive for Aerococcus urinae, echocardiography revealed vegetations on the mitral valve with severe mitral insufficiency. After two weeks of antibiotic treatment, mitral valve replacement was performed, from which the patient recovered. Reports of Aerococcus urinae endocarditis are still limited in number. On the other side, Aerococcus urinae is an emerging bacterial uropathogen with greater relevance than previously believed. We review the case reports of Aerococcus urinae endocarditis and newest literature about its presentation, course, and clinical management.

3.
Clin Chim Acta ; 560: 119737, 2024 Jun 15.
Artigo em Inglês | MEDLINE | ID: mdl-38768699

RESUMO

INTRODUCTION: Proper implementation of Point-of-Care testing (POCT) for C-reactive protein (CRP) in primary care can decrease the inappropriate use of antibiotics, thereby tackling the problem of growing antimicrobial resistance. OBJECTIVE: The analytical performance and user-friendliness of four POCT-CRP assays were evaluated: QuikRead go easy, LumiraDx, cobas b 101 and Afinion 2. MATERIALS AND METHODS: Imprecision was evaluated using plasma pools in addition to manufacturer-specific control material. Trueness was assessed by verification of traceability to ERM-DA474/IFCC in parallel to method comparison towards the central laboratory CRP method (cobas c 503) using i) retrospectively selected plasma samples (n = 100) and ii) prospectively collected capillary whole blood samples (n = 50). User-friendliness was examined using a questionnaire. RESULTS: Between-day imprecision on plasma pools varied from 4.5 % (LumiraDx) to 11.5 % (QuikRead). Traceability verification revealed no significant difference between cobas c 503 CRP results and the ERM-DA474/IFCC certified value. cobas b 101 and Afinion achieved the best agreement with the central laboratory method. LumiraDx and QuikRead revealed a negative mean difference, with LumiraDx violating the criterion of > 95 % of POCT-CRP-results within ± 20 % of the comparison method. Regarding user-friendliness, Afinion obtained the highest Likert-scores. CONCLUSION: The analytical performance and user-friendliness of POCT-CRP devices varies among manufacturers, emphasizing the need for quality assurance supervised by a central laboratory.


Assuntos
Proteína C-Reativa , Sistemas Automatizados de Assistência Junto ao Leito , Proteína C-Reativa/análise , Humanos , Sistemas Automatizados de Assistência Junto ao Leito/normas , Testes Imediatos
4.
Eur J Med Res ; 29(1): 120, 2024 Feb 13.
Artigo em Inglês | MEDLINE | ID: mdl-38350996

RESUMO

BACKGROUND: Bronchiectasis is a chronic airway disease characterized by permanent and irreversible abnormal dilatation of bronchi. Several studies have reported the development of bronchiectasis after renal transplantation (RT), but no prospective study specifically assessed bronchiectasis in this population. This study aimed to compare features of patients with bronchiectasis associated with RT to those with idiopathic bronchiectasis. METHODS: Nineteen patients with bronchiectasis associated with RT (RT-B group) and 23 patients with idiopathic bronchiectasis (IB group) were prospectively included in this monocentric cross-sectional study. All patients underwent clinical, functional, laboratory, and CT scan assessments. Sputum was collected from 25 patients (n = 11 with RT-B and n = 14 with IB) and airway microbiota was analyzed using an extended microbiological culture. RESULTS: Dyspnea (≥ 2 on mMRC scale), number of exacerbations, pulmonary function tests, total bronchiectasis score, severity and prognosis scores (FACED and E-FACED), and quality of life scores (SGRQ and MOS SF-36) were similar in the RT-B and IB groups. By contrast, chronic cough was less frequent in the RT-B group than in the IB group (68% vs. 96%, p = 0.03). The prevalence and diversity of the airway microbiota in sputum were similar in the two groups. CONCLUSION: Clinical, functional, thoracic CT scan, and microbiological characteristics of bronchiectasis are overall similar in patients with IB and RT-B. These results highlight that in RT patients, chronic respiratory symptoms and/or airway infections should lead to consider the diagnosis of bronchiectasis. Further studies are required to better characterize the pathophysiology of RT-B including airway microbiota, its incidence, and impact on therapeutic management.


Assuntos
Bronquiectasia , Transplante de Rim , Doença Pulmonar Obstrutiva Crônica , Humanos , Estudos Transversais , Transplante de Rim/efeitos adversos , Qualidade de Vida , Bronquiectasia/complicações
5.
Prog Transplant ; 32(4): 321-326, 2022 12.
Artigo em Inglês | MEDLINE | ID: mdl-36047000

RESUMO

Introduction: Liver grafts with limited steatosis are currently used for liver transplantation, but the natural history of graft steatosis is not well known. Project Aims or Questions: This program evaluation aimed at assessing changes of steatosis after liver transplantation. Design: A retrospective chart review was performed assessing presence and severity of steatosis in the liver explant and in time zero donor graft biopsies carried out at the time-point of liver transplantation on histopathology and on imaging one year thereafter in 30 well characterized patients. Results: Ten patients (33%) showed steatosis on explant. Time zero biopsy revealed steatosis in 18 grafts (60%) and no steatosis in 12 (40%). One year after transplantation, 8 patients (27%) had steatosis and 22 patients (63%) had none. Fourteen patients (47%) showed changes in steatosis: 12 showed resolution and 2 showed de novo steatosis. Explant macrovesicular steatosis was associated with presence of steatosis 1 year after transplantation (binary logistic regression model, p = 0.014), but not macrovesicular steatosis in the donor graft at time-point of transplantation. Conclusion: Resolution of graft steatosis was frequent. Presence of steatosis in the recipient's liver, but not graft steatosis, was a risk factor for steatosis 1 year after transplantation. Factors related to the recipient seem to prevail over donor-related factors in determining the persistence or de novo appearance of steatosis after liver transplantation.


Assuntos
Fígado Gorduroso , Transplante de Fígado , Humanos , Transplante de Fígado/efeitos adversos , Transplante de Fígado/métodos , Estudos Retrospectivos , Fígado Gorduroso/patologia , Fígado/diagnóstico por imagem , Doadores de Tecidos , Biópsia , Sobrevivência de Enxerto
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA